ANI Pharmaceuticals, Inc. (ANIP) Return on equity 2016–2025
ANI Pharmaceuticals, Inc. (ANIP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.4%FY2025 · since FY2016: 2.3% → 14.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.4% | +19.1 pp |
| FY2024 | -4.7% | -9.1 pp |
| FY2023 | 4.4% | +19.7 pp |
| FY2022 | -15.3% | -2.4 pp |
| FY2021 | -12.9% | -1.4 pp |
| FY2020 | -11.5% | -14.4 pp |
| FY2019 | 2.9% | -5.0 pp |
| FY2018 | 7.9% | +8.5 pp |
| FY2017 | -0.6% | -2.9 pp |
| FY2016 | 2.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice